vimarsana.com

Page 100 - ஒன்றுபட்டது மாநிலங்களில் மையங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hope rising for Lassa fever vaccine

Punch Newspapers Sections IT is heartening that efforts are ongoing to develop a vaccine for Lassa fever. An American biotechnology company, INOVIO, which is spearheading the research, noted that the first participant in Lassa vaccine trial had been dosed in a Phase 1B clinical trial for INO-4500, its DNA vaccine candidate for Lassa fever. The clinical trial in progress in Ghana is reportedly focusing on offering precisely-designed DNA medicines to treat and protect people from infectious diseases and cancer. Lassa fever, according to the United States Centres for Disease Control and Prevention, is an animal-borne, or zoonotic, acute viral illness. It is endemic in parts of West Africa, including Sierra Leone, Liberia, Guinea and Nigeria. The illness was discovered in 1969 and is named after the town in Nigeria where the first cases occurred. The CDC says an estimated 100,000 to 300,000 infections of Lassa fever occur annually, with approximately 5,000 deaths. The World Health O

WHO publishes materials that aim to provide high-quality care to people affected by lymphatic filariasis

WHO publishes materials that aim to provide high-quality care to people affected by lymphatic filariasis RTI International/Nguyen Minh Duc Truong Van Duc receives care for his lymphedema caused by lymphatic filariasis. © Credits 5 March 2021 Reading time: The World Health Organization (WHO) has updated an aide-mémoire for programme managers to help them provide high-quality care to people suffering from lymphoedema and other consequences of lymphatic filariasis, a debilitating neglected tropical disease (NTD) endemic in 72 countries affecting tens of millions of people. first published in 2013, has been updated to describe the essential package of care for lymphoedema, hydrocele and episodes of adenolymphangitis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.